公开(公告)号：US20240358759A1

公开(公告)日：2024-10-31

申请号：US18657954

申请日：2024-05-08

申请人： WUGEN, Inc.

发明人： Ayman KABAKIBI ,  Ryan P. SULLIVAN

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61P35/00 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2863 ,  C07K2317/31

摘要： Disclosed herein is method of treating cancer comprising administration of memory NK cells and a monoclonal antibody comprising a tumor antigen binding moiety and a CD16 binding moiety. Also disclosed herein is a method for treating ovarian cancer in a patient in need thereof comprising contacting ovarian cancer cells or gastric cancer cells with memory NK cells in combination with an anti-HER2 monoclonal antibody. Also disclosed herein is a method for treating head and neck cancer or colorectal cancer in a patient in need thereof comprising contacting head and neck cancer cells or colorectal cancer cells with memory NK cells in combination with an anti-EGFR monoclonal antibody. Also disclosed herein is a method for treating urothelial carcinoma, head and neck cancer, colorectal cancer, or gastric cancer cells in a patient in need thereof comprising contacting the cancer cells with memory NK cells in combination with an anti-PDL-1 monoclonal antibody.

公开(公告)号：US20240101668A1

公开(公告)日：2024-03-28

申请号：US18447138

申请日：2023-08-09

申请人： WUGEN, Inc.

发明人： Ayman KABAKIBI ,  Alexander S. HAMIL

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P37/04 ,  C12N15/86

CPC分类号： C07K16/2803 ,  A61K39/4611 ,  A61K39/4631 ,  A61P37/04 ,  C07K16/2851 ,  C07K16/2863 ,  C12N15/86 ,  A61K2239/11 ,  A61K2239/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C12N2740/15043

摘要： Disclosed herein are polypeptides, such as monoclonal antibodies (mAbs) and functional fragments thereof, synthetic antigen-binding proteins such as single-chain variable fragments (scFvs), and chimeric antigen receptors (CARs), that can specifically recognize tumor-associated antigens (TAAs) on cancer cells, for example those that express CD33, FLT3, and CLL-1, useful in the treatment of diseases such as cancer.

公开(公告)号：US20200147137A1

公开(公告)日：2020-05-14

申请号：US16679127

申请日：2019-11-08

申请人： WUGEN, Inc.

发明人： John MCKEARN ,  Ayman KABAKIBI ,  You W. ZHOU

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K14/715 ,  C12N15/85

摘要： Disclosed herein are transmembrane proteins comprising at least two chains, each chain comprising an endodomain, a transmembrane domain, and an ectodomain; wherein the ectodomains of the at least two chains of the transmembrane protein interact together to bind to a drug or soluble protein; wherein the endodomains of the at least two chains of the transmembrane protein together comprise a structure functionally similar to that of an IL-2 receptor endodomain, an IL-7 receptor endodomain, or an IL-15 receptor endodomain; and wherein binding of the drug or soluble protein to the ectodomain activates IL-2, IL-7, or IL-15 signaling in CAR-bearing immune effector cells.